QIAGEN expands biomarker content portfolio to support greater use of molecular diagnostics for immuno-oncology therapies
Option to add new biomarkers for microsatellite instability (MSI) and mismatch repair (MMR) to QIAGEN’ s NGS panels Hilden, Germany, and Germantown, Maryland, June 3, 2017 – QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received a worldwide license from The Johns Hopkins University for biomarkers that have been shown to play... Read more